Future research should explore combination therapies involving gp350-CAR-T cells alongside immune checkpoint inhibitors like PD-1/PD-L1 inhibitors [33, 34] to enhance CAR-T cell persistence and prevent tumor evasion [35–37]. Here, CD274 is linked to neoplasm.